Epkinly access in Bangladesh: the DGDA named-patient pathway
How patients in the People's Republic of Bangladesh legally obtain Epkinly (epcoritamab-bysp) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Bangladesh access Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after two or more lines of prior systemic therapy through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Bangladeshi patients need Epkinly through the named-patient pathway
The People's Republic of Bangladesh operates a structured pharmaceutical regulatory environment. Epkinly (epcoritamab-bysp) is regulated through DGDA (Directorate General of Drug Administration) channels, and a Bangladeshi family asking for Epkinly is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Epkinly's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Bangladesh or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the DGDA named-patient pathway is the mechanism that connects a Bangladeshi-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Epkinly is a subcutaneously administered bispecific CD20-directed CD3 T-cell engager with step-up dosing during cycle 1 to mitigate cytokine release syndrome, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Epkinly in Bangladesh
Epkinly (epcoritamab-bysp; Genmab / AbbVie) is a subcutaneous bispecific CD20 x CD3 T-cell engager for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma after two or more prior lines of systemic therapy. As of 2026-05-31, no DGDA marketing authorisation for epcoritamab is publicly indexed on the DGDA Registered Imported Drugs list. Bangladesh haematology files for the drug therefore route under the case-by-case import permission mechanism of Section 13 of the Drugs (Control) Ordinance 1982.
The boxed-warning cytokine-release-syndrome and immune-effector-cell-associated-neurotoxicity-syndrome (ICANS) risk profile is determinative for where Epkinly can be dispensed in Bangladesh. The FDA prescribing information requires Cycle 1 step-up dosing (0.16 mg / 0.8 mg / 48 mg) in a setting where the patient can be observed for at least 24 hours after the first full dose, with immediate access to advanced life support, tocilizumab availability for CRS management, and a neuro-assessment workflow for ICANS. The DGDA file must specify the inpatient-or-extended-observation arrangement.
For Cycles 2 and 3 the once-weekly subcutaneous dosing transitions to a more outpatient-feasible cadence; for Cycle 4 onward the schedule becomes once every two weeks; for Cycle 9 onward dosing is once every four weeks. The file specifies the multi-month dosing plan and the cycle-by-cycle setting.
Last DGDA bulletin observed touching imported biologic regulation: 2025-01-14 Guideline for Quality Assurance of Locally Sourced Medical Products. Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Bangladesh where Epkinly is dispensed
Epcoritamab Cycle 1 requires an inpatient-or-extended-observation environment with CRS / ICANS management capability. The set of Bangladeshi centres equipped to run a CRS protocol is small:
- Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka - Department of Haematology and the developing BMT unit; the academic centre most experienced with bispecific T-cell engager protocols nationally.
- National Institute of Cancer Research and Hospital (NICRH), Dhaka - Haematological Malignancies service; inpatient lymphoma cycles are routinely run here.
- Square Hospitals Limited, Dhaka - private multi-specialty tertiary; haematology, intensive-care backup, and tocilizumab stock on-site.
- Evercare Hospital Dhaka, Dhaka - private multi-specialty tertiary; haematology service with established CRS-monitoring SOP from CD19 CAR-T-adjacent experience.
- Combined Military Hospital (CMH), Dhaka - tertiary haematology service for military and selected civilian referrals.
The Cycle 1 dispensing requirement effectively concentrates Epkinly access at four to five Dhaka-based centres; Cycles 2+ can transition to outpatient dispensing at the same centre but cross-city transfer to a centre lacking CRS protocol is not routine.
Local pricing reference for Epkinly in Bangladesh
US WAC reference for Epkinly (epcoritamab-bysp; 4 mg/0.8 mL and 48 mg/0.8 mL prefilled vials for subcutaneous injection) is in the order of USD 24,000 to USD 30,000 per month at the FDA-labelled cycle-by-cycle dosing pattern for a steady-state patient. Cycle 1 carries inpatient observation and tocilizumab-on-standby costs that are not part of the drug line. Source: Epkinly FDA Prescribing Information.
No public BDT reference price for epcoritamab has been observed on DGDA, BSMMU, or major-importer published lists as of 2026-05-31. Importers customarily quote BDT at the spot USD/BDT rate published by Bangladesh Bank on the day of the proforma invoice plus permit, cold-chain logistics, and Cycle-1 inpatient overhead. An itemised quotation is issued at intake with the day-of-quote conversion shown.
Price snapshot date: 2026-05-31. Cycle-1 inpatient observation, tocilizumab access, and ICANS-monitoring imaging are billed separately by the dispensing hospital.
Country-specific access barriers for Epkinly in Bangladesh
The hard barrier for Epkinly in Bangladesh is the CRS / ICANS protocol requirement, not the DGDA paperwork. Cycle 1 must be administered in a hospital that can run a CRS pathway. The number of Bangladeshi centres with documented CRS protocols and tocilizumab stock is in the single digits, concentrated in Dhaka. For a patient living outside Dhaka, Cycle 1 typically requires a documented inpatient admission at one of the Dhaka centres above, with subsequent outpatient cycles transferable.
Public-sector funding for bispecific T-cell engagers in Bangladesh is constrained. The Ministry of Health and Family Welfare procurement budget covers rituximab biosimilar and standard R-CHOP for first-line DLBCL; subsequent-line bispecific therapy is not on the locally-procured drug list. The Honourable Prime Minister's Welfare Fund processes case-by-case grant applications, and lymphoma cases have historically been approved on individual merit; timing is not predictable.
Private health insurance penetration in Bangladesh is low; group-corporate plans (Pragati Life, Delta Life, MetLife Bangladesh, Green Delta, Pioneer) cover formal-sector employees with annual maximums that typically cover one to two months of epcoritamab. Out-of-pocket self-pay supplemented by family remittances and Ahsania Mission Cancer & General Hospital charitable subsidy is the dominant funding pattern. AbbVie and Genmab patient-access programmes operate regionally; Bangladeshi access is policy-specific.
Cold-chain logistics for subcutaneous prefilled vials at 2 to 8 degree Celsius is established at Dhaka airport; tocilizumab on-site stock at the dispensing hospital is the binding clinical-readiness criterion. The dispensing hospital pharmacy file lists tocilizumab availability explicitly because DGDA review on bispecific T-cell-engager files frequently asks for this confirmation.
Recent local regulatory news touching Epkinly or its drug class in Bangladesh
No DGDA bulletin specifically naming epcoritamab or the CD20 x CD3 bispecific drug class has been observed in the last twelve months on the DGDA all-categories notices page as of 2026-05-31. Adjacent context relevant to the import workflow:
- 2025-01-14 - DGDA Guideline for Quality Assurance of Locally Sourced Medical Products affects how biologic lots routed via the institutional-import channel are QA-checked at the hospital pharmacy. Source: DGDA Guideline PDF.
- The Bangladesh medicine-regulation reform Bill in active consultation may rename the case-by-case import-permission mechanism that currently underpins bispecific-T-cell-engager access. Source: Dhaka Tribune coverage.
What your physician needs to provide
For a Bangladeshi-licensed specialist prescribing Epkinly through the DGDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after two or more lines of prior systemic therapy, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Epkinly is the appropriate next step given a subcutaneously administered bispecific CD20-directed CD3 T-cell engager with step-up dosing during cycle 1 to mitigate cytokine release syndrome.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Epkinly (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Bangladeshi license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Epkinly in Bangladesh
Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Epkinly is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by DGDA? The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.
Can I receive Epkinly at home? The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Epkinly cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Epkinly specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Epkinly case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.
Next step
If your Bangladeshi physician has prescribed Epkinly and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.